Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm.
Pawlyn C, Schjesvold FH, Cairns DA, Wei LJ, Davies F, Nadeem O, Abdulhaq H, Mateos MV, Laubach J, Weisel K, Ludwig H, Rajkumar SV, Sonneveld P, Jackson G, Morgan G, Richardson PG.
Pawlyn C, et al. Among authors: ludwig h.
Blood Cancer J. 2024 Aug 12;14(1):134. doi: 10.1038/s41408-024-01109-4.
Blood Cancer J. 2024.
PMID: 39134544
Free PMC article.
Review.